Table 1 Baseline patient characteristics

From: Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

 

Total (n = 34)

Age (years), median (IQR)

41(32,67)

 >40 year—n (%)

18 (52.9)

Menopausal status

 Premenopausal

17 (50)

 Menopausal

17 (50)

ECOG status, n (%)

 0

34 (100)

 1

0

HER2 status score, n (%)

 IHC 0-1

29 (85.3)

 IHC 2+

5 (14.7)

Ki-67 level, n (%)

 ≤30%

8 (23.5)

 >30%

26 (76.5)

Clinical T stage, n (%)

 T1

1 (2.9)

 T2

22 (64.7)

 T3

10 (29.4)

 T4

1 (2.9)

Clinical N stage, n (%)

 N0

7 (20.6)

 N1

19 (55.9)

 N2

2 (5.9)

 N3

6 (17.6)

Overall clinical stage, n (%)

 Stage II

20 (58.8)

 Stage III

14 (41.2)

PD-L1 status, n (%)a

 Positive

24 (70.6)

 Negative

6 (17.6)

 Unknown

4 (11.8)

  1. IQR interquartile range, ECOG eastern cooperative oncology group, HER2 human epidermal growth factor receptor 2
  2. aPD-L1 positive is defined as a combined positive score of ≥1
Back to article page